It is designed to be given in a single shot at birth or a baby’s first season of RSV.
It can also be given as a larger dose in a second RSV season in children who are highly vulnerable.Most cases are mild, but it’s the leading cause of hospitalization among infants.
In trials, the shot was found to lower the risk of RSV needing medical attention by 75% and the risk of hospitalization by 78%.While the FDA isn’t required to follow the committee’s recommendations, it usually does.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
US FDA panel backs Sanofi-AstraZeneca's preventive RSV therapyThe U.S. Food and Drug Administration advisers on Thursday backed the use of Sanofi and partner AstraZeneca's experimental antibody to prevent respiratory syncytial virus (RSV) infections in infants.
Read more »
FDA panel recommends injectable drug to prevent RSV in infantsThe monoclonal antibody shot would be given to babies during or before their first RSV season, as well as to high-risk children up to age 2 entering their second RSV season.
Read more »
FDA advisors recommend AstraZeneca antibody to protect babies from RSVIf the Food and Drug Administration approves nirsevimab, it will be the first medical intervention available in the U.S. that can protect infants from RSV.
Read more »
FDA panel weighs US approval for Alzheimer's drug from Eisai and BiogenA panel of expert advisers on Friday began their meeting to discuss whether to recommend traditional U.S. regulatory approval for Eisai and Biogen's new Alzheimer's drug Leqembi, a move expected to expand Medicare payment for the treatment.
Read more »
5 things to know for June 9: Trump, Air quality, Stocks, RSV, Ukraine | CNNHere are 5⃣ things to know today. 1⃣ Trump indicted 2⃣ Air quality set to improve 3⃣ S&P 500 in bull market territory 4⃣ RSV treatment for infants 5⃣ Ukraine dam collapse
Read more »